Progress in clinical neurosciences: cognitive markers of progression in Alzheimer's disease
- PMID: 16018149
- DOI: 10.1017/s0317167100003917
Progress in clinical neurosciences: cognitive markers of progression in Alzheimer's disease
Abstract
The objective of this review is to summarize the literature on Alzheimer's disease progression utilizing cognitive batteries to track change over time. Studies published in English and obtained through PubMed searches (1983-2004) were included (i) if they had a longitudinal design and followed probable Alzheimer's patients diagnosed by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association or Diagnostic and Statistical Manual III/IV criteria, and (ii) if the techniques used for serial assessment were well-established in terms of validity and reliability. Longitudinal studies examining Alzheimer's disease progression report highly variable annual rates of change in decline rate. It remains unclear if this reflects disease subgroups or stage-related rate of decline. In conclusion a combination of stage-appropriate cognitive tests such as the Mattis Dementia Rating Scale and the Severe Impairment Battery, along with appropriate statistical methods to account for individual variability in decline rates, can capture the progression of Alzheimer disease and may be useful in further investigation.
Similar articles
-
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.Arch Gen Psychiatry. 2011 Sep;68(9):961-9. doi: 10.1001/archgenpsychiatry.2011.96. Arch Gen Psychiatry. 2011. PMID: 21893661
-
Changes over time in memory, processing speed and clock drawing tests help to discriminate between vascular cognitive impairment, mild cognitive impairment and Alzheimer's disease.Neurol Res. 2004 Jul;26(5):481-7. doi: 10.1179/016164104225016209. Neurol Res. 2004. PMID: 15362213
-
[Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].Encephale. 2003 May-Jun;29(3 Pt 1):266-72. Encephale. 2003. PMID: 12876552 French.
-
Target symptoms and outcome measures: cognition.Can J Neurol Sci. 2007 Mar;34 Suppl 1:S42-6. doi: 10.1017/s0317167100005552. Can J Neurol Sci. 2007. PMID: 17469681 Review.
-
Neuropsychological assessment in the diagnosis of Alzheimer's disease.Curr Protoc Neurosci. 2009 Oct;Chapter 10:Unit10.3. doi: 10.1002/0471142301.ns1003s49. Curr Protoc Neurosci. 2009. PMID: 19802814 Free PMC article. Review.
Cited by
-
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine.J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1312-7. doi: 10.1136/jnnp.2007.141648. Epub 2008 Jun 27. J Neurol Neurosurg Psychiatry. 2008. PMID: 18586865 Free PMC article. Clinical Trial.
-
Cognitive and functional progression of dementia in two longitudinal studies.Int J Geriatr Psychiatry. 2019 Nov;34(11):1623-1632. doi: 10.1002/gps.5175. Epub 2019 Jul 26. Int J Geriatr Psychiatry. 2019. PMID: 31318090 Free PMC article.
-
Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper.J Nutr Health Aging. 2010 Feb;14(2):121-30. doi: 10.1007/s12603-010-0023-z. J Nutr Health Aging. 2010. PMID: 20126960
-
Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease.Neuropsychiatr Dis Treat. 2013;9:1629-35. doi: 10.2147/NDT.S49895. Epub 2013 Oct 23. Neuropsychiatr Dis Treat. 2013. PMID: 24187498 Free PMC article.
-
Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.Alzheimers Res Ther. 2014 Aug 18;6(4):48. doi: 10.1186/alzrt280. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 25484926 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical